05.06.22
Open Book Extracts (OBX), a cGMP-certified manufacturer and distributor of cannabinoid ingredients and finished products, has completed phase one of its toxicology and safety assessment of the company’s cannabinoid ingredients cannabigerol (CBG), cannabinol (CBN), and cannabichromene (CBC).
OBX contracted scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the toxicological studies investigating the safety of CBG, CBN, and CBC that will support a Generally Recognized As Safe (GRAS) independent conclusion or New Dietary Ingredient (NDI) application.
The report concluded that the test articles were non-mutagenic, non-clastogenic, and non-genotoxic. The battery of GLP/OECD compliant studies is a “major contribution in the advancement of the science of hemp-derived CBD,” OBX said, adding that this investment in toxicological assessment demonstrates its commitment to furthering the science behind cannabinoid ingredients.
“Until today, there have been no comprehensive toxicological safety assessments completed on minor cannabinoids, including CBG, CBN, and CBC,” said Chelsea Pipkin, OBX vice president of quality assurance. “The completion and publication of these safety studies on these ingredients in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”
Dave Neundorfer, CEO of OBX added: “We are thrilled to advance cannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS or NDI status. As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all cannabinoid manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”
OBX contracted scientific and regulatory consulting firm, AIBMR Life Sciences, Inc, to conduct the toxicological studies investigating the safety of CBG, CBN, and CBC that will support a Generally Recognized As Safe (GRAS) independent conclusion or New Dietary Ingredient (NDI) application.
The report concluded that the test articles were non-mutagenic, non-clastogenic, and non-genotoxic. The battery of GLP/OECD compliant studies is a “major contribution in the advancement of the science of hemp-derived CBD,” OBX said, adding that this investment in toxicological assessment demonstrates its commitment to furthering the science behind cannabinoid ingredients.
“Until today, there have been no comprehensive toxicological safety assessments completed on minor cannabinoids, including CBG, CBN, and CBC,” said Chelsea Pipkin, OBX vice president of quality assurance. “The completion and publication of these safety studies on these ingredients in a peer-reviewed academic journal specializing in toxicology is a monumental step forward in putting competent and reliable science behind a product. The public should applaud this effort as well as the time and expense it required.”
Dave Neundorfer, CEO of OBX added: “We are thrilled to advance cannabinoid science and are very pleased with the safety results from this landmark study. This is an important milestone in our pursuit of GRAS or NDI status. As an organization, our commitment to safety remains paramount. We look forward to setting the bar for all cannabinoid manufacturers in the market and encourage them to conduct similar toxicological assessments on their own base raw materials.”
